中国烧伤创疡杂志
中國燒傷創瘍雜誌
중국소상창양잡지
2011年
1期
68-83
,共16页
Mallmoud F.Sakr%陈永翀%Alamed K.Al-Batanouny%Ibrahim Salina%张勇%李世兵%黄桂美
Mallmoud F.Sakr%陳永翀%Alamed K.Al-Batanouny%Ibrahim Salina%張勇%李世兵%黃桂美
Mallmoud F.Sakr%진영충%Alamed K.Al-Batanouny%Ibrahim Salina%장용%리세병%황계미
MEBO%生理性湿润环境%再生医学%压力性溃疡%慢性创面%愈合指数
MEBO%生理性濕潤環境%再生醫學%壓力性潰瘍%慢性創麵%愈閤指數
MEBO%생이성습윤배경%재생의학%압력성궤양%만성창면%유합지수
MEBO%physiological moist environment%regenerative medicine%pressure ulcers%chronic wounds%healing index
目的 评估湿润烧伤膏(MEBO)治疗慢性压力性溃疡的效果和安全性.方法 将来自世界不同国家和地区的5家医院的87名慢性压力性溃疡病例(182个创面)随机分成两组,实验组为MEBO组(n=41),对照组为Fucidin组(n=46);前瞻性收集的数据包括人口统计学、营养状况、潜在性疾病和并发症.分别按照各组的创面处理规范治疗创面,每2周计算和比较溃疡面的面积(SA)和愈合指数(HI).结果 两组都具有相同的统计学、临床、生化和溃疡特征.在持续使用MEBO治疗12周的过程中,在第2周和第4周可以观察到溃疡创面的愈合指数大幅度上升,溃疡创面明显减小.通过MEBO治疗的病例,半数以上(56.5%)的溃疡创面在12周之内都完全愈合(HI=1);通过Fucidin(P<0.001)治疗的对照组病例,只有19.6%的溃疡创面完全愈合.在连续12周的治疗中,MEBO组病例的溃疡创面没有HI<50%的,而在.Fucidin(P<0.001)治疗的对照组中,26.8%的病例HI<50%.两组均未出现不良反应与过敏症状.结论 MEBO能够在治疗开始2周后快速促进不同程度慢性压力性溃疡创面的愈合,并且HI增长明显.在12周之内,MEBO能够完全促进50%以上的创面愈合.
目的 評估濕潤燒傷膏(MEBO)治療慢性壓力性潰瘍的效果和安全性.方法 將來自世界不同國傢和地區的5傢醫院的87名慢性壓力性潰瘍病例(182箇創麵)隨機分成兩組,實驗組為MEBO組(n=41),對照組為Fucidin組(n=46);前瞻性收集的數據包括人口統計學、營養狀況、潛在性疾病和併髮癥.分彆按照各組的創麵處理規範治療創麵,每2週計算和比較潰瘍麵的麵積(SA)和愈閤指數(HI).結果 兩組都具有相同的統計學、臨床、生化和潰瘍特徵.在持續使用MEBO治療12週的過程中,在第2週和第4週可以觀察到潰瘍創麵的愈閤指數大幅度上升,潰瘍創麵明顯減小.通過MEBO治療的病例,半數以上(56.5%)的潰瘍創麵在12週之內都完全愈閤(HI=1);通過Fucidin(P<0.001)治療的對照組病例,隻有19.6%的潰瘍創麵完全愈閤.在連續12週的治療中,MEBO組病例的潰瘍創麵沒有HI<50%的,而在.Fucidin(P<0.001)治療的對照組中,26.8%的病例HI<50%.兩組均未齣現不良反應與過敏癥狀.結論 MEBO能夠在治療開始2週後快速促進不同程度慢性壓力性潰瘍創麵的愈閤,併且HI增長明顯.在12週之內,MEBO能夠完全促進50%以上的創麵愈閤.
목적 평고습윤소상고(MEBO)치료만성압력성궤양적효과화안전성.방법 장래자세계불동국가화지구적5가의원적87명만성압력성궤양병례(182개창면)수궤분성량조,실험조위MEBO조(n=41),대조조위Fucidin조(n=46);전첨성수집적수거포괄인구통계학、영양상황、잠재성질병화병발증.분별안조각조적창면처리규범치료창면,매2주계산화비교궤양면적면적(SA)화유합지수(HI).결과 량조도구유상동적통계학、림상、생화화궤양특정.재지속사용MEBO치료12주적과정중,재제2주화제4주가이관찰도궤양창면적유합지수대폭도상승,궤양창면명현감소.통과MEBO치료적병례,반수이상(56.5%)적궤양창면재12주지내도완전유합(HI=1);통과Fucidin(P<0.001)치료적대조조병례,지유19.6%적궤양창면완전유합.재련속12주적치료중,MEBO조병례적궤양창면몰유HI<50%적,이재.Fucidin(P<0.001)치료적대조조중,26.8%적병례HI<50%.량조균미출현불량반응여과민증상.결론 MEBO능구재치료개시2주후쾌속촉진불동정도만성압력성궤양창면적유합,병차HI증장명현.재12주지내,MEBO능구완전촉진50%이상적창면유합.
Objectives A multi-centers,randomized,controlled study to assess the efficacy and safety of MEBO(Julphar Gulf Pharmaceutical Industries,UAE,and SanTou MEBO Pharmaceutical CO.,LTD.,China)in healing of chronic pressure ulcers.Subjects and Methods Eighty seven patients with 182chronic pressure ulcers treated at five hospitals from different areas in world,between January 2003 and January 2009,were randomized into 2 groups; those in group 1(n = 46)received MEBO while those in group 2(n =41)received Fucidin(Leo Pharmaceutical,Denmark).Data collected prospectively included demographics,nutritional status,underlying predisposing disease and co-morbidities.Ulcer surface area(SA)and healing index(HI)were calculated and compared at two-week intervals for 12 weeks.Results Patients in both groups had similar demographic,clinical,biochemical features,and ulcer characteristics.There was a significant increase in HI and reduction in ulcer SA on weeks two and four respectively,that was maintained through 12 weeks in patients treated with MEBO.More than half of ulcers(56.5%)treated with MEBO had complete healing(HI = 1)by 12 weeks,as opposed to only 19.6% of those treated with Fucidin(P <0.001).Moreover,none of the patients receiving MEBO had a HI of <50% of their ulcers by 12 weeks as compared to 26.8% of those receiving Fucidin(P<0.001).No adverse effects or allergic reactions of topical ointment were encountered in either group.Conclusions In addition to its safety,MEBO significantly promotes the healing of chronic pressure ulcers with significant increase in HI of any given ulcer as early as two weeks following initiation of treatment,and complete healing of more than 50% of ulcers by 12 weeks.
